Allosteric WNK Kinase Inhibitors are primarily used in the treatment of hypertension and related cardiovascular conditions. These inhibitors work by targeting the With-No-Lysine (WNK) kinases, which play a crucial role in regulating blood pressure through the control of sodium and potassium balance in the kidneys. By inhibiting WNK kinases, these compounds help reduce sodium reabsorption, leading to a decrease in blood pressure. This makes them particularly valuable for patients who do not respond well to traditional antihypertensive therapies. Additionally, research is exploring their potential in treating other conditions such as kidney diseases and certain types of cancer where WNK signaling pathways are implicated. Their allosteric mechanism offers a selective approach, minimizing off-target effects and enhancing therapeutic efficacy.